Last reviewed · How we verify
Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
Naphazoline hydrocloride + Pheniramine Maleate + Panthenol is a Sympathomimetic agent and antihistamine Small molecule drug developed by EMS. It is currently in Phase 3 development for Redness and congestion of the eyes due to allergic rhinitis or other conditions.
Naphazoline hydrochloride is a sympathomimetic agent that acts as an alpha-adrenergic agonist, while pheniramine maleate is an antihistamine that exerts its effects by competitively inhibiting the action of histamine at the H1 receptor. Panthenol, a form of vitamin B5, has moisturizing and soothing properties.
Naphazoline hydrochloride is a sympathomimetic agent that acts as an alpha-adrenergic agonist, while pheniramine maleate is an antihistamine that exerts its effects by competitively inhibiting the action of histamine at the H1 receptor. Panthenol, a form of vitamin B5, has moisturizing and soothing properties. Used for Redness and congestion of the eyes due to allergic rhinitis or other conditions.
At a glance
| Generic name | Naphazoline hydrocloride + Pheniramine Maleate + Panthenol |
|---|---|
| Sponsor | EMS |
| Drug class | Sympathomimetic agent and antihistamine |
| Target | Alpha-adrenergic receptor (alpha-1 adrenergic receptor) and H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Naphazoline hydrochloride works by stimulating the alpha-adrenergic receptors in the nasal mucosa, leading to vasoconstriction and reduction of nasal congestion. Pheniramine maleate, on the other hand, blocks the action of histamine at the H1 receptor, which is responsible for the symptoms of allergic rhinitis. Panthenol helps to soothe and moisturize the nasal mucosa, providing additional relief from nasal congestion and discomfort.
Approved indications
- Redness and congestion of the eyes due to allergic rhinitis or other conditions
Common side effects
- Dry mouth
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naphazoline hydrocloride + Pheniramine Maleate + Panthenol CI brief — competitive landscape report
- Naphazoline hydrocloride + Pheniramine Maleate + Panthenol updates RSS · CI watch RSS
- EMS portfolio CI
Frequently asked questions about Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
What is Naphazoline hydrocloride + Pheniramine Maleate + Panthenol?
How does Naphazoline hydrocloride + Pheniramine Maleate + Panthenol work?
What is Naphazoline hydrocloride + Pheniramine Maleate + Panthenol used for?
Who makes Naphazoline hydrocloride + Pheniramine Maleate + Panthenol?
What drug class is Naphazoline hydrocloride + Pheniramine Maleate + Panthenol in?
What development phase is Naphazoline hydrocloride + Pheniramine Maleate + Panthenol in?
What are the side effects of Naphazoline hydrocloride + Pheniramine Maleate + Panthenol?
What does Naphazoline hydrocloride + Pheniramine Maleate + Panthenol target?
Related
- Drug class: All Sympathomimetic agent and antihistamine drugs
- Target: All drugs targeting Alpha-adrenergic receptor (alpha-1 adrenergic receptor) and H1 receptor
- Manufacturer: EMS — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Redness and congestion of the eyes due to allergic rhinitis or other conditions
- Compare: Naphazoline hydrocloride + Pheniramine Maleate + Panthenol vs similar drugs
- Pricing: Naphazoline hydrocloride + Pheniramine Maleate + Panthenol cost, discount & access